Holen Sie sich die Stockscreener-App
15.45
10.12%
1.42
Handel nachbörslich:
15.45
Dyne Therapeutics Inc Aktie (DYN) Neueste Nachrichten
Why Dyne Therapeutics Inc. stock is seen as undervaluedJuly 2025 Market Mood & High Yield Equity Trading Tips - newser.com
Analyzing recovery setups for Dyne Therapeutics Inc. investorsVolume Spike & Weekly High Momentum Picks - newser.com
Dyne Therapeutics Inc.’s volatility index tracking explainedWeekly Market Summary & Real-Time Price Movement Reports - newser.com
Is Dyne Therapeutics Inc. reversing from oversold territory2025 Trade Ideas & Real-Time Stock Movement Alerts - newser.com
What recovery options are there for Dyne Therapeutics Inc.2025 Pullback Review & Real-Time Stock Price Movement Reports - newser.com
How moving averages guide Dyne Therapeutics Inc. tradingLong Setup & Weekly Watchlist of Top Performers - newser.com
Using RSI to spot recovery in Dyne Therapeutics Inc.Portfolio Risk Report & Fast Exit Strategy with Risk Control - newser.com
Is Dyne Therapeutics Inc. stock gaining market shareJuly 2025 Fed Impact & Free Community Supported Trade Ideas - newser.com
Will Dyne Therapeutics Inc. stock deliver better than expected guidanceSell Signal & Free Safe Entry Trade Signal Reports - newser.com
Dyne Therapeutics Inc. (DYN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Does Dyne Therapeutics Inc. fit your quant trading modelWeekly Trend Report & AI Powered Market Entry Strategies - newser.com
Sector ETF performance correlation with Dyne Therapeutics Inc.Market Performance Recap & Risk Controlled Stock Alerts - newser.com
Dyne Therapeutics (NASDAQ:DYN) Shares Gap Down After Analyst Downgrade - MarketBeat
Oppenheimer Downgrades Dyne Therapeutics (NASDAQ:DYN) to Market Perform - MarketBeat
Dyne Therapeutics (DYN) Sees Downgrade by Oppenheimer | DYN Stock News - GuruFocus
Dyne Therapeutics (DYN) Is Up 17.0% After Positive One-Year ACHIEVE Trial Data for Z-Basivarsen – Has The Bull Case Changed? - Yahoo Finance
Heatmap analysis for Dyne Therapeutics Inc. and competitorsJuly 2025 Weekly Recap & Reliable Volume Spike Trade Alerts - newser.com
Signal strength of Dyne Therapeutics Inc. stock in tech scannersMarket Volume Summary & Stock Portfolio Risk Management - newser.com
Will Dyne Therapeutics Inc. stock keep outperforming rivalsMarket Weekly Review & Daily Growth Stock Investment Tips - newser.com
What moving averages say about Dyne Therapeutics Inc.2025 Investor Takeaways & AI Enhanced Trading Signals - newser.com
Can Dyne Therapeutics Inc. stock hit analyst price targets2025 Historical Comparison & Advanced Swing Trade Entry Plans - newser.com
Weiss Ratings Reaffirms Sell (D-) Rating for Dyne Therapeutics (NASDAQ:DYN) - MarketBeat
What machine learning models say about Dyne Therapeutics Inc.2025 Technical Overview & Low Volatility Stock Recommendations - newser.com
Is Dyne Therapeutics Inc. stock a smart buy before Fed meetingJuly 2025 Rallies & AI Driven Stock Reports - newser.com
Dyne: Accelerated Approval Established Endpoint Sets Stage For DM1 Data In Mid-2026 - Seeking Alpha
Stocks With Rising Relative Price Strength: Dyne Therapeutics - Investor's Business Daily
Dyne Therapeutics Skyrockets on Breakthrough Data – Inside the Surge, Financials & 2026 Catalysts - ts2.tech
Dyne Therapeutics (NASDAQ:DYN) Trading Up 10.8%Here's Why - MarketBeat
Dyne Therapeutics rises on positive data from myotonic dystrophy trial - Seeking Alpha
Dyne Therapeutics (DYN) Reports Encouraging Phase 1/2 Trial Resu - GuruFocus
Dyne Therapeutics Reports Strength, Function Improvement From Myotonic Dystrophy Drug Candidate in Ongoing Early Phase Trial - MarketScreener
What drives Dyne Therapeutics Inc stock priceTechnical Pattern Recognition & Free Exceptional ROI Methods - earlytimes.in
Dyne Therapeutics, Inc. Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 - MarketScreener
Dyne Therapeutics reports positive one-year data for DM1 treatment By Investing.com - Investing.com Nigeria
Dyne Therapeutics (NASDAQ:DYN) Shares Down 4.7%Here's Why - MarketBeat
Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen for Myotonic Dystrophy Type 1 - Investing News Network
Dyne Therapeutics reports positive one-year data for DM1 treatment - Investing.com India
Dyne Therapeutics Reports Significant One-Year Clinical Data for Zeleciment Basivarsen in Patients with Myotonic Dystrophy Type 1 - Quiver Quantitative
Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) - The Manila Times
Applying big data sentiment scoring on Dyne Therapeutics Inc.2025 Buyback Activity & Daily Profit Focused Screening - newser.com
Applying Elliott Wave Theory to Dyne Therapeutics Inc.Market Risk Summary & Capital Protection Trade Alerts - newser.com
Technical signs of recovery in Dyne Therapeutics Inc.Quarterly Portfolio Report & AI Powered Market Entry Strategies - newser.com
Using Python tools to backtest Dyne Therapeutics Inc. strategiesPortfolio Performance Summary & Fast Moving Trade Plans - newser.com
What risks investors should watch in Dyne Therapeutics Inc. stock2025 Bull vs Bear & Technical Pattern Based Buy Signals - newser.com
Dyne Therapeutics Inc. stock momentum explainedJuly 2025 Outlook & Growth Oriented Trade Recommendations - newser.com
Dyne’s Investigational DMD Drug DYNE-251 Gets Japan Orphan Drug Status After Strong Trial Data - Insider Monkey
Dyne Therapeutics Elects Brian Posner to Board - The Globe and Mail
Dyne Therapeutics' Valuation Leaves No Room For Error (NASDAQ:DYN) - Seeking Alpha
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):